| 舒冰,方玉婷,张圣雨,等.替罗非班用于急性冠脉综合征致药品不良反应 39例分析[J].安徽医药,2020,24(1):206-209. |
| 替罗非班用于急性冠脉综合征致药品不良反应 39例分析 |
| Analysis of 39 cases of adverse drug reactions in patients with acute coronary syndrome by tirofiban |
| |
| DOI：10.3969/j.issn.1009?6469.2020.01.052 |
| 中文关键词: 急性冠状动脉综合征 血小板聚集抑制剂 血小板糖蛋白 GPⅡb?Ⅲa复合物 血小板减少 出血 药物毒性 药物监测 替罗非班 |
| 英文关键词: Acute coronary syndrome Platelet aggregation inhibitors Platelet glycoprotein GPⅡb?Ⅲa complex Thrombocy? topenia Hemorrhage Drug toxicity Drug monitoring Tirofiban |
| 基金项目: |
|
| 摘要点击次数: 2124 |
| 全文下载次数: 621 |
| 中文摘要: |
| 目的探讨替罗非班用于急性冠脉综合征( ACS)病人致药品不良反应的特点和防治措施。方法收集中国科学技术大学附属第一医院(安徽省立医院) 2013年 1月至 2017年 5月共 39例替罗非班药品不良反应报告( ADR)进行分析、归纳和总结，并重点对替罗非班诱导的血小板减少情况给予分析和总结。结果 39例 ADR中，男 33例，女 6例，男女比为 5.5∶1；70～80岁病人最多 13例( 33.33%)；主要累及器官 /系统为血液系统 29例( 64.44%)主要临床表现为出血 32例( 71.11%)和血小板减少 8例( 17.78%)等；出血不良反应类型以牙龈出血和鼻衄居多，分别为 13例(占，28.89%)和 7例(占 15.56%)。 5例严重的 ADR中， 1例严重的胃肠道出血， 1例红细胞减少， 3例血小板减少。结论临床应加强替罗非班用药安全性监测，尤其应重点监测替罗非班诱导的血小板减少症和出血的发生，保障病人用药安全。 |
| 英文摘要: |
| Objective To investigate the general characteristics，prevention and control measures of adverse drug reactions for tirofi? ban to patients with acute coronary syndrome.Methods To collect The ADR cases of the total of 39 cases adverse drug reaction reports of tirofibanin，collected in our hospital from January 2013 to May 2013，were analyzed and summarized，focusing on the thrombocytopenia induced by tirofiban.Results:In 39 cases of adverse drug reactions，the proportion of males and females was 5.5∶ 1，with statistically significant difference(P＜0.05).The proportion of 70?79 years old patients was the most(33.33%).The main progressive organ/system was blood system(64.44%)，and the main clinical manifestations were hemorrhage(71.11%)and throm? bocytopenia(17.78%).Adverse drug reactions of haemorrhagic were mainly of gingival hemorrhage and nasal nosebleed，respectively28.89% and 15.56%.In 5 cases of severe ADR，1 case of severe gastrointestinal bleeding，1 case of red blood cell decrease，and 3 cases of thrombocytopenia.Conclusion:It is necessary to strengthen the monitoring of drug use in tirofiban，especially monitor the oc? currence of thrombocytopenia and hemorrhage induced by tirofiban，and ensure the safety of drug use. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
